Objectives: In pediatric acute respiratory distress syndrome, lung injury is mediated by immune activation and severe inflammation. Therefore, we hypothesized that patients with elevated pro-and antiinflammatory cytokines would have higher mortality rates and that these biomarkers could improve risk stratification of poor outcomes. Design: Multicenter prospective observational study. Setting: We enrolled patients from five academic PICUs between 2008 and 2015. Patients: Patients were 1 month to 18 years old, used noninvasive or invasive ventilation, and met the American European Consensus Conference definition of acute respiratory distress syndrome. Interventions: Eight proinflammatory and anti-inflammatory cytokines were measured on acute respiratory distress syndrome day 1 and correlated with mortality, ICU morbidity as measured by survivor Pediatric Logistic Organ Dysfunction score, and biomarkers of endothelial injury, including angiopoietin-2, von Willebrand Factor, and soluble thrombomodulin. Measurements and Main Results: We measured biomarker levels in 194 patients, including 38 acute respiratory distress syndrome nonsurvivors. Interleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis factor-R2 were each strongly associated with all-cause mortality, multiple markers of ICU morbidity, and endothelial injury. A multiple logistic regression model incorporating oxygenation index, interleukin-8, and tumor necrosis factor-R2 was superior to a model of oxygenation index alone in predicting the composite outcome of mortality or severe morbidity (area under the receiver operating characteristic, 0.77 [0.70-0.83] vs 0.70 [0.62-0.77]; p = 0.042). Conclusions: In pediatric acute respiratory distress syndrome, pro-and anti-inflammatory cytokines are strongly associated with mortality, ICU morbidity, and biochemical evidence of endothelial injury. These cytokines significantly improve the ability of the oxygenation index to discriminate risk of mortality or severe morbidity and may allow for identification and enrollment of high-risk subgroups for future studies. (Crit Care Med 2017; 45:858-866) 
P ediatric acute respiratory distress syndrome (ARDS) is a clinically heterogeneous disorder characterized by injury to the alveolar-capillary interface, resulting in significant impairment of oxygenation (1, 2) . This syndrome is associated with 15-20% mortality and substantial morbidity among survivors (3, 4) , yet imprecision in identifying high-risk patients early in their course limits the application of experimental therapies that might further improve outcomes. Although triggering events include both local and systemic insults, a common pathway is the resultant inflammatory cascade that mediates both pulmonary endothelial and alveolar epithelial damage (5, 6) .
A principal component of this inflammatory cascade is the release of chemokines such as interleukin (IL)-8 and macrophage inflammatory protein (MIP)-1β by local antigen presenting cells and endothelial cells, leading to migration of activated neutrophils to the lungs (7, 8) and subsequent release of cytokines such as IL-6 and tumor necrosis factor (TNF)-α (9, 10) . In concert, these mechanisms lead to an increase in lung endothelial permeability and ongoing immune activation, which can further propagate the cycle of cell damage (11, 12) . We have previously identified evidence of this cell damage in pediatric ARDS patients by correlating mortality with circulating markers of endothelial cell injury, including angiopoietin-2 (Ang-2), von Willebrand Factor (vWF), and soluble thrombomodulin (sTM) (13, 14) . To date, however, little direct evidence exists linking systemic immune activation with pediatric ARDS outcomes or markers of endothelial damage.
We therefore undertook this study to correlate circulating proand anti-inflammatory cytokine levels in pediatric ARDS patients with mortality, morbidity, and biomarkers of endothelial injury. We used a commercially available multiplex panel of 21 cytokines related to macrophage, neutrophil, T cell, and B-cell activation (Supplemental Fig. 1 , Supplemental Digital Content 1, http:// links.lww.com/CCM/C469), retained only those reliably detected above the lower limit of quantitation (LLOQ), and then analyzed the performance characteristics of these biomarkers according to consensus guidelines for biomarker development (15) (16) (17) (18) . We hypothesized that elevated cytokine levels would correlate with clinical outcomes and markers of endothelial damage in pediatric ARDS and might augment the prognostic utility of the oxygenation index (OI) in predicting mortality and morbidity.
METHODS

Patients
Daily screening occurred at five PICUs between 2008 and 2015. Inclusion criteria were 1) 30 days < age ≤18 years, 2) respiratory support of either continuous positive airway pressure, bi-level positive airway pressure, or invasive mechanical ventilation, and 3) ARDS or acute lung injury as defined by the American European Consensus Conference (19) . Exclusion criteria were corrected gestational age less than 36 weeks and limitation of care precluding endotracheal intubation. This study was approved by the Institutional Review Board at each center with consent obtained from each patient/surrogate.
Measurements
All cytokine measurements were carried out on plasma samples collected within 24 hours of onset of ARDS (hereafter referred to as "ARDS day 1"). As daily pediatric phlebotomy restrictions limited available blood volume for research, we used a multiplex immunoassay to measure interferon-γ, IL-1α, IL-1β,  IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6 IL-7, IL-8, IL-10, IL-12 , IL-15, IL-17, IL-18, IL-23, MIP-1α, MIP-1β, TNF-α, and TNF-R2 and an ultrasensitive immunoassay to repeat measurement of TNF-α (Myriad RBM, Austin, TX) (supplemental text, Supplemental Digital Content 1, http://links.lww.com/CCM/ C469). Only cytokines measured above the LLOQ in greater than or equal to 75% of patients were included in the analysis.
Primary Outcomes
We measured associations between cytokines and two primary outcomes: 1) all-cause hospital mortality and 2) survivor morbidity, estimated by the highest survivor Pediatric Logistic Organ Dysfunction (PELOD) score of measurements taken on days 1-7, 14, 21, and 28 (20) . To optimize statistical power for multivariable regression, we combined these two outcomes into a composite outcome of either mortality or severe morbidity, defined as the top quartile of survivor PELOD score.
Secondary Outcomes
We measured associations between cytokines and day 1 ARDS severity, estimated by the Pao 2 /Fio 2 ratio (P/F ratio), the OI, and the Pediatric Risk of Mortality (PRISM)-3 score, the latter solely in cases where ARDS day 1 coincided with PICU day 0 or 1 (supplemental text, Supplemental Digital Content 1, http:// links.lww.com/CCM/C469) (21) . When an arterial line was not present, Pao 2 was imputed from Spo 2 less than or equal to 97% according to a log-linear equation (22) . Finally, we measured associations between day 1 cytokines and three biomarkers of endothelial injury (Ang-2, vWF, and sTM) (13, 14) .
Confounding Variables
To account for underlying variation in cytokine levels due to demographic diversity, we adjusted for age, sex, and patientreported race (23) (24) (25) . We also tested for relationships with a history of hematopoietic cellular transplantation (HCT), which we have previously shown to significantly impact pediatric ARDS outcomes and plasma biomarkers (26) (27) (28) .
Statistics
Selection of variables for logistic regression models used the least angle regression methodology, which employs forward stagewise selection to identify and rank regression variables according to their correlation with outcome and then maximizes parsimony by identifying among equally robust models the model with the least prediction error (29 
RESULTS
Patient Characteristics and Outcomes
Of 284 enrolled patients, 194 had adequate plasma available for cytokine measurements and were included in this study (Supplemental Table 1 , Supplemental Digital Content 1, http:// links.lww.com/CCM/C469). Of these 194, 107 were male (55%), 135 were Caucasian (70%), and the median age was 4.9 years (interquartile range [IQR] , 0.9-11.5 yr) ( Table 1) . Patients were admitted to the PICU a median of 1 day before ARDS onset (IQR, 0-2) and on the first day after ARDS onset (ARDS day 1), the median P/F ratio was 136.5 (IQR, 90.1-218), the median OI was 9.4 (IQR, 5.3-18.3), and 176 patients received conventional mechanical ventilation (91%). All-cause hospital mortality occurred in 38 patients (20%) and median survivor PELOD score and ICU length of stay (LOS) were 20 (IQR, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 
and 12 days (IQR, 8-19 d).
Elevations in Inflammatory Cytokines Are Strongly Associated With Mortality
Five proinflammatory cytokines (IL-6, IL-8, IL-18, MIP-1β, and TNF-α) and three anti-inflammatory cytokines (IL-1RA, IL-10, and TNF-R2) were measured above the LLOQ in greater than or equal to 75% of patients and were included in subsequent analyses.
Univariate Analysis. When stratified by mortality, nonsurvivors had significantly higher levels of IL-6, IL-8, IL-18, IL-10, and TNF-R2 than survivors ( Fig. 1 and Table 2 ). The AUROCs for discriminating mortality for the eight cytokines ranged from 0.53 to 0.68 and were highest for IL-8 (0.68; 95% CI, 0.60-0.77); none were significantly different than that of the OI (0.70; 95% CI, 0.62-0.77) (Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/C469).
Adjusted Analysis. In order to account for potential confounders to these relationships, we adjusted for age, sex, race, OI, and history of HCT, the latter being associated with significantly higher levels of multiple inflammatory markers including IL-8, IL-18, and TNF-R2 (Supplemental Table 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/ C469). After adjustment, elevated IL-6 and IL-8 remained significantly associated with increased odds of mortality (Supplemental Table 4 , Supplemental Digital Content 1, http://links.lww.com/CCM/C469). All eight assessed biomarkers were each positively correlated with the OI and PRISM-3 score, and IL-6, IL-8, IL-18, IL-1RA, IL-10, and TNF-R2 were each negatively correlated with the P/F ratio (Supplemental Table 5 
Elevations in Inflammatory Cytokines Are Associated With Survivor ICU Morbidity
To assess morbidity in survivors, we examined the relationships between day 1 cytokines, survivor PELOD score, and ICU LOS. Day 1 IL-6, IL-8, IL-18, MIP-1β, TNF-α, IL-10, and TNF-R2 were each strongly associated with elevated PELOD score after adjustment for age, sex, and race (Supplemental Table 6 , Supplemental Digital Content 1, http://links.lww.com/ CCM/C469). The strongest correlation was observed between PELOD and TNF-R2 (ρ = 0.430; p < 0.001). Increasing quartile of survivor PELOD was significantly associated with greater levels of all cytokines (Supplemental Fig. 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/C469). Elevated MIP-1β and TNF-R2 were weakly associated with increased survivor ICU LOS.
Elevations in Inflammatory Cytokines Are Associated With Biomarkers of Endothelial Injury
In order to associate cytokines with biochemical evidence of endothelial injury, we measured correlations between cytokines and plasma Ang-2, vWF, and sTM. IL-6, IL-8, TNF-α, IL-10, and TNF-R2 were each positively correlated with Ang-2, and IL-8, IL-1RA, IL-10, and TNF-R2 were each positively correlated with sTM (Supplemental Table 7 , Supplemental Digital Content 1, http://links.lww.com/CCM/C469). The strongest correlations were observed between IL-6 and Ang-2 (ρ = 0.463; p < 0.001) and between IL-8 and Ang-2 (ρ = 0.443; p < 0.001).
Elevations in Inflammatory Cytokines Help Distinguish Risk of Mortality or Severe Morbidity
Given this evidence, we used the least angle regression methodology to select variables for a regression model that would improve risk stratification of the OI ratio by incorporating biomarker levels. To maximize statistical power, we combined our two primary outcomes into a composite outcome of either mortality or severe morbidity, defined as the top quartile of survivor PELOD score (PELOD ≥ 30). The model with maximum parsimony and minimum prediction error included the OI, IL-8, and TNF-R2 and predicted the composite outcome with a five-fold internally cross-validated AUROC of 0.77 (95% CI, 0.70-0.83). Compared with the OI alone (AUROC, 0.70; 95% CI, 0.62-0.77), this model had significantly greater fit (likelihood ratio test, p < 0.001) and AUROC (p = 0.042) (Fig. 2) .
We then used the least angle regression methodology to test an expanded set of variables including the OI, HCT status, any of the eight measured cytokines, and any of the three biomarkers of endothelial injury. The expanded model with maximum parsimony and minimum prediction error included the OI, HCT status, IL-6, IL-8, IL-10, and TNF-R2, predicted mortality or severe morbidity with an internally cross-validated AUROC of 0.79 (95% CI, 0.72-0.86) and was well calibrated over each quartile (Hosmer-Lemeshow goodness-of-fit, p = 0.903) (Supplemental Table 8 When we divided patients into quartiles of risk according to the expanded model, we found that 74% of those in the highest quartile of risk died or had severe morbidity (sensitivity, 74%; specificity, 72%; likelihood ratio, 2.7 [95% CI, 2.0-3.7]). This was significantly greater than the 64% rate of death or severe morbidity for those in the top quartile of risk according to the OI alone (sensitivity, 64%; specificity, 69%; likelihood ratio, 2.0 [95% CI, 1.5-2.8]; McNemar's p = 0.025). The majority of patients who reached the outcome of death or severe morbidity did so in the first 2 weeks of ICU stay ( Supplemental Fig. 4 , Supplemental Digital Content 1, http:// links.lww.com/CCM/C469). 
Elevations in Inflammatory Cytokines Improve Pediatric Acute Lung Injury Consensus Conference (PALICC) Risk Stratification
The next goal was to assess whether risk stratification according to PALICC-defined ARDS severity could be improved by the addition of cytokine levels (31) . ARDS severity on day 1 was strongly associated with both mortality (10% for mild [ Fig. 3 ). We found similar results in analogous comparisons using IL-10 and TNF-R2 (Supplemental Table 9 , Supplemental Digital Content 1, http://links.lww.com/CCM/C469).
DISCUSSION
In this study, we measured plasma levels of pro-and anti-inflammatory cytokines in 194 pediatric ARDS patients. We found a strong relationship between mortality and elevated plasma levels of both proinflammatory (IL-6, IL-8, IL-18, MIP-1β, and TNF-α) and anti-inflammatory cytokines (IL-1RA, IL-10, and TNF-R2). These cytokines were also associated with ICU morbidity as measured by survivor PELOD score, early physiologic evidence of lung and multiple organ injury, as evidenced by P/F ratio, OI, and the PRISM-3 score, and biochemical evidence of endothelial injury, including elevated plasma Ang-2 and sTM. Finally, we found that the addition of inflammatory cytokines to the OI improves risk stratification in a heterogeneous ARDS population. To our knowledge, this is the largest multicenter study of inflammatory pathways in pediatric ARDS and the first of its size to identify significant early systemic cytokine perturbations in pediatric ARDS nonsurvivors. This important finding builds upon work done in both adult clinical studies and animal models, which have identified alveolar neutrophilic infiltration and cytokine release as hallmark findings of ARDS (10, (32) (33) (34) (35) (36) . Although several studies in pediatrics have associated cytokinemia with meconium aspiration, influenza, and sepsis, this is the first to study a broad range of pro-and anti-inflammatory cytokines in a rigorously defined ARDS framework (37-39). In terms of prognostic information, we identified significantly improved risk stratification when OI was combined with day 1 cytokines. For example, among patients with PALICC-defined severe ARDS, those with IL-8 levels above the cohort median had nearly twice the rate of mortality or severe morbidity than those with IL-8 levels below the cohort median (p = 0.039). Also, when the top quartile of risk according to OI, IL-6, IL-8, IL-10, TNF-R2, and HCT was compared with the top quartile of risk according to OI alone, there was a 15% increase in relative risk for death or severe morbidity (McNemar's p = 0.025). If applied in a prospective fashion in our cohort, this expanded model would have identified an additional five children of 47 in the top quartile days-to-weeks before the development of death or severe morbidity, allowing for enrollment in research protocols of experimental therapies.
Ultimately, improved risk stratification is crucial for the identification of candidate high-risk subgroups for the development of new therapeutics, particularly in pediatrics where a major challenge of clinical trials has been attainment of goal accrual. Once they become widely available, rapid molecular assays could make bedside risk stratification for clinical trials enrollment a feasible goal and could represent a paradigm shift for PICU research.
Our study is part of a growing body of pediatric critical care research to use a composite outcome combining mortality and morbidity (40, 41) . Neither the mortality rate in our cohort (38/194) nor in that of Yehya et al (42) (37/283) is sufficiently high to power a multivariable logistic regression associating mortality with OI and multiple cytokines. Therefore, we generated a composite outcome of mortality or severe morbidity, defined as the top quartile of survivor PELOD (≥ 30). This outcome was met by 77 of 194 patients and facilitated an appropriately powered logistic regression allowing us to show that the composite biomarker of OI, IL-8, and TNF-R2 outperformed the model of OI alone (p = 0.042). The composite outcome of mortality or severe morbidity is biologically appropriate, clinically relevant, and meets recent PALICC and Collaborative Pediatric Critical Care Research Network recommendations for attention to morbidity as a significant PICU outcome (41) .
In terms of subgroup phenotyping, we identified higher levels of IL-8, IL-18, IL-10, and TNF-R2 in HCT ARDS patients relative to non-HCT ARDS patients. Recent data suggest that HCT patients may have unique inflammatory derangements after transplantation that might differentiate mortality risk (43, 44) . Clinical experience with pulmonary dysfunction during neutrophil engraftment as well as early success of TNF-α inhibition support the exaggerated role of inflammation in this population (45, 46) . Although our ability to draw further conclusions was limited by the size of this subgroup, this analysis is an important first step in identifying clinically validated molecular markers that differentiate subgroups of risk. Further work in identifying unique molecular phenotypes is critical to understanding the pathophysiologic heterogeneity of pediatric ARDS. Our study has several strengths. First, given the cohort size and diversity of patient characteristics, our results likely have external validity with respect to other academic PICUs. Second, in addition to assessing mortality, we assessed ICU morbidity and biochemical evidence of endothelial injury. The former has been recently emphasized by the PALICC and is particularly important given the lower mortality rates in children in comparison to adults (41, 47) , whereas the latter lends biologic and mechanistic plausibility to our findings. Third, we increased our sample size by 15% by imputing Pao 2 from Spo 2 less than or equal to 97% in 26 patients lacking an arterial line but otherwise meeting enrollment criteria.
Our study has some limitations. First, our models were derived in a large pediatric cohort but do require external validation. We attempted to address this by using five-fold internal cross-validation to minimize error without reducing sample size (30) . Second, we did not mandate a uniform ventilator weaning protocol and could not account for variability in ventilator management patterns as they might influence our primary outcomes.
CONCLUSIONS
In conclusion, there was a significant association between mortality and elevated day 1 plasma cytokines in children with ARDS. These cytokines were also associated with ARDS illness severity, including the P/F ratio, OI, and PRISM-3 score; with ICU morbidity, including survivor ICU LOS and PELOD score; and with biochemical evidence of endothelial injury, including elevated plasma Ang-2 and sTM. These cytokines improve the prognostic performance of the OI in discriminating risk of mortality or severe morbidity and may allow for identification and enrollment of high-risk subgroups for future clinical trials.
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